Cost-effectiveness analysis of an 18-week exercise programme for patients with breast and colon cancer undergoing adjuvant chemotherapy: the randomised PACT study
ObjectiveMeta-analyses show that exercise interventions during cancer treatment reduce cancer-related fatigue. However, little is known about the cost-effectiveness of such interventions. Here we aim to assess the cost-effectiveness of the 18-week physical activity during cancer treatment (PACT) int...
Saved in:
Published in | BMJ open Vol. 7; no. 3; p. e012187 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BMJ Publishing Group LTD
01.03.2017
BMJ Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | ObjectiveMeta-analyses show that exercise interventions during cancer treatment reduce cancer-related fatigue. However, little is known about the cost-effectiveness of such interventions. Here we aim to assess the cost-effectiveness of the 18-week physical activity during cancer treatment (PACT) intervention for patients with breast and colon cancer. The PACT trial showed beneficial effects for fatigue and physical fitness.DesignCost-effectiveness analyses with a 9-month time horizon (18 weeks of intervention and 18 weeks of follow-up) within the randomised controlled multicentre PACT study.SettingOutpatient clinics of 7 hospitals in the Netherlands (1 academic and 6 general hospitals)Participants204 patients with breast cancer and 33 with colon cancer undergoing adjuvant treatment including chemotherapy.InterventionSupervised 1-hour aerobic and resistance exercise (twice per week for 18 weeks) or usual care.Main outcome measuresCosts, quality-adjusted life years (QALY) and the incremental cost-effectiveness ratio.ResultsFor colon cancer, the cost-effectiveness analysis showed beneficial effects of the exercise intervention with incremental costs savings of €4321 and QALY improvements of 0.03. 100% of bootstrap simulations indicated that the intervention is dominant (ie, cheaper and more effective). For breast cancer, the results did not indicate that the exercise intervention was cost-effective. Incremental costs were €2912, and the incremental effect was 0.01 QALY. At a Dutch threshold value of €20 000 per QALY, the probability that the intervention is cost-effective was 2%.ConclusionsOur results suggest that the 18-week exercise programme was cost-effective for colon cancer, but not for breast cancer.Trial registration numberISRCTN43801571. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-News-2 ObjectType-Feature-3 content type line 23 |
ISSN: | 2044-6055 2044-6055 |
DOI: | 10.1136/bmjopen-2016-012187 |